<i>In vitro</i> experiments demonstrated that BaP treatment was associated with increased RRM2 expression in prostate cancer cells, while baicalin treatment reduced this effect, providing preliminary experimental support for the bioinformatic predictions.<h4>Conclusion</h4>This study delineates a potential mechanistic framework by which BaP may be associated with PCa progression through multi-target and multi-pathway mechanisms, highlighting RRM2 as a candidate core mediator. The gene discussed is RRM2; the disease is posterior cortical atrophy.